Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

WPP FY revenues slide as Q4 performance disappoints

(Sharecast News) - Advertising firm WPP posted worse-than-expected revenues on Thursday as weaker discretionary spending amongst its UK, North American and Chinese clients resulted in a disappointing Q4 performance for the company. Revenue less pass-through costs was down 1% on a like-for-like basis at £11.35bn in FY24, missing analyst estimates for a smaller 04% decline, with Q4 revenues down 2.3% year-on-year.

The FTSE 100-listed firm said UK revenues were down 5.1% in Q4, while North American revenues slipped 1.4%. Chinese revenues crashed 21.2% during the final quarter of the year.

However, WPP said FY headline operating profits rose 2.0% on a like-for-like basis to £1.71bn, in line with market expectations, while adjusted free cash flow improved to £738.0m on the back of strong working capital management and an increase in operating profit margins from 14.8% to 15.0%.

As far as FY25 was concerned, WPP expects organic revenues to fall between 0% and 2%, with its overall performance likely to improve in H2.

"Though we remain cautious given the overall macro environment, we are confident in our medium-term targets and believe our focus on innovation, a simpler client-facing offer and operational excellence will support our growth and deliver greater value for our shareholders," said chief executive Mark Read.

WPP also stated it was now looking to expand its AI-powered platform, WPP Open, with AI investment increasing to £300.0m as it looks to increase its competitiveness in the market.

As of 0830 GMT, WPP shares had sunk 16.28% to 644.80p.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.